Blue Jet Healthcare Ltd
Blue Jet Healthcare Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments. The company expects stable to improving revenues in the contrast media segment over the next 12-18 months, driven by commercial-scale launch of new iodinated intermediates and growth in the NCE molecule for MRI.
From Blue Jet Healthcare Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments.
- Capacity expansions at Vizag (103 acres) and backward integration facility at Mahad are on track, with Phase-I at Vizag targeting completion by FY '28, adding 1,000 KL capacity over 2-3 years.
- Growth in the cardiovascular drug segment (notably Bempedoic Acid) is expected to continue, with triple-digit percentage growth reported and approvals in new markets like Japan expanding opportunities.
- Contrast media shipments faced transit delays but volumes and revenues are expected to normalize and sustain at FY '23 levels over the next 12-18 months.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Blue Jet Healthcare is expanding capacity with a major CAPEX plan including a new 103-acre site in Vizag.
- Phase-I of Vizag project, with an approximate CAPEX of Rs. 1,000 crores, will have 4 blocks: 2 for Contrast Media, 1 for high-intensity Sweetener, and 1 multipurpose block including peptide fragments for GLPs; expected completion by FY '28.
- Backward integration facility at Mahad with a CAPEX of about Rs. 300 crores (increased from Rs. 250 crores due to automation); commissioning expected by H2 FY '26.
- A state-of-the-art R&D center is planned in Hyderabad at a cost of Rs. 40 crores to enhance capabilities including peptides, GLP1 intermediates, and biocatalysts.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The order book visibility for contrast media (marketed product) remains stable as per management comments.
- The order book for intermediates, specifically for the NCE molecule, is noted to be encouraging.
- Commercial scale supply for iodinated intermediates expected to commence in Q4 of the financial year.
- Management emphasized a long-term view on capacity build-up aligned with orders, indicating visibility over 5 years, though ramp-up timing may vary by 12-18 months.
- Customer off-take and schedules cause some quarter-on-quarter volatility but overall order book remains solid.
- Growth prospects for Pharma Intermediate segment, including Bempedoic Acid and other chronic disease molecules, supported by good order visibility and new approvals.
2 more points management made on order book & pipeline
Blue Jet Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹235 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Blue Jet Health's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key concall takeaways from Morepen Laboratories Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key concall takeaways from Anuh Pharma Ltd's Q2 FY26 earnings call — and how it…
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key concall takeaways from Themis Medicare Ltd's Q2 FY26 earnings call…
Frequently Asked Questions
What were Blue Jet Healthcare Ltd Q2 FY26 results?
The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments. The company expects stable to improving revenues in the contrast media segment over the next 12-18 months, driven by commercial-scale launch of new iodinated intermediates and growth in the NCE molecule for MRI.
What is Blue Jet Healthcare Ltd share price analysis?
Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹11,063 Cr. Investors should review the full earnings analysis for detailed insights.
Is Blue Jet Healthcare Ltd planning capital expenditure?
Blue Jet Healthcare is expanding capacity with a major CAPEX plan including a new 103-acre site in Vizag. - Phase-I of Vizag project, with an approximate CAPEX of Rs.
Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.